SCHEMBL269548

SCHEMBL269548

CCCCCCCC1CCC(c2ccc(C(=O)Oc3ccc(N=C=S)cc3)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.44
PRSS1 P07477 5/20 0.43
ACR P10323 4/20 0.43
MAPT P10636 4/20 0.42
LMNA P02545 3/20 0.42
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPK1 P28482 1/20 0.40
NPC1 O15118 2/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
HPGD P15428 1/20 0.37
MGLL Q99685 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10972576 0.86 CYP2C9 (0.59) CYP2C9PRSS1ACRMAPTLMNA
SCHEMBL10972573 0.86 CYP2C9 (0.59) CYP2C9PRSS1ACRMAPTLMNA
SCHEMBL10972575 0.86 CYP2C9 (0.59) CYP2C9PRSS1ACRMAPTLMNA
SCHEMBL3799919 0.86 MEN1 (0.42) CYP2C9MAPTLMNAALDH1A1MEN1
SCHEMBL3761254 0.86 MEN1 (0.42) CYP2C9MAPTLMNAALDH1A1MEN1
SCHEMBL3761250 0.86 MEN1 (0.42) CYP2C9MAPTLMNAALDH1A1MEN1
SCHEMBL9052415 0.86 MEN1 (0.42) CYP2C9MAPTLMNAALDH1A1MEN1
SCHEMBL3799918 0.86 MEN1 (0.42) CYP2C9MAPTLMNAALDH1A1MEN1
SCHEMBL9052414 0.86 MEN1 (0.42) CYP2C9MAPTLMNAALDH1A1MEN1
Fluoride SCHEMBL9841471 0.85 CYP2C9 (0.47) CYP2C9PRSS1ACRMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180052111-A1 SUBSTRATES, DEVICES, AND METHODS FOR QUANTITATIVE LIQUID CRYSTAL ASSAYS PLATYPUS TECHNOLOGIES, LLC 2018-02-22 US disclosed
US-9816147-B2 Liquid crystal based analyte detection PLATYPUS TECHNOLOGIES, LLC (US) 2017-11-14 US disclosed
US-9816147-B2 Liquid crystal based analyte detection PLATYPUS TECHNOLOGIES, LLC (US) 2017-11-14 US disclosed
US-9797843-B2 Substrates, devices, and methods for quantitative liquid crystal assays PLATYPUS TECHNOLOGIES, LLC (US) 2017-10-24 US disclosed
US-9797843-B2 Substrates, devices, and methods for quantitative liquid crystal assays PLATYPUS TECHNOLOGIES, LLC (US) 2017-10-24 US disclosed
US-20170212088-A1 DETECTION OF GAS-PHASE ANALYTES USING LIQUID CRYSTALS PLATYPUS TECHNOLOGIES, LLC 2017-07-27 US disclosed
US-20170212088-A1 DETECTION OF GAS-PHASE ANALYTES USING LIQUID CRYSTALS PLATYPUS TECHNOLOGIES, LLC 2017-07-27 US disclosed
US-9575037-B2 Detection of gas-phase analytes using liquid crystals PLATYPUS TECHNOLOGIES, LLC (US) 2017-02-21 US disclosed
US-9575037-B2 Detection of gas-phase analytes using liquid crystals PLATYPUS TECHNOLOGIES, LLC (US) 2017-02-21 US disclosed
US-20160274084-A1 DETECTION OF VAPOR PHASE COMPOUNDS BY CHANGES IN PHYSICAL PROPERTIES OF A LIQUID CRYSTAL PLATYPUS TECHNOLOGIES, LLC 2016-09-22 US disclosed
US-7662572-B2 Compositions and liquid crystals PLATYPUS TECHNOLOGIES, LLC. (US) 2010-02-16 US disclosed
US-7651662-B2 Rubbed substrate surfaces; activation; uniform anchoring of liquid crystals WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2010-01-26 US disclosed
US-20100009344-A1 LIQUID CRYSTAL BASED ANALYTE DETECTION PLATYPUS TECHNOLOGIES, LLC (US) 2010-01-14 US disclosed
US-7531366-B2 Bead based assays using a liquid crystal reporter PLATYPUS TECHNOLOGIES, LLC (US) 2009-05-12 US disclosed
US-20080268546-A1 DETECTION OF DNA HYBRIDIZATION ON SURFACES WISCONSIN ALUMNI RESEARCH FOUNDATION 2008-10-30 US disclosed
US-20080160539-A1 Substrates, devices, and methods for cellular assays PLATYPUS TECHNOLOGIES, LLC (US) 2008-07-03 US disclosed
US-20070178534-A1 Using liquid crystal support comprising chemotactic and chemokinetic agents to monitor cell migration and invasion; diagnosing cancer NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-08-02 US disclosed
US-20070099249-A1 Compositions and liquid crystals PLATYPUS TECHNOLOGIES, LLC (US) 2007-05-03 US disclosed
US-20070042505-A1 Liquid crystal based analyte detection PLATYPUS TECHNOLOGIES, LLC (US) 2007-02-22 US disclosed
US-20070004046-A1 Detection of analytes PLATYPUS TECHNOLOGIES, LLC (US) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099249-A1 Compositions and liquid crystals FABP5, FABP1, SSB CYP2C9 3739/4885PRSS1 2095/4885ACR 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.